https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13491
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13491
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADFamotidine by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of ledipasvir .
Possible decrease of clinical efficacy.
Monitor for clinical efficacy.
–
–
Administrer at the same time and/or 12 hours after the combined drug.
Recommended dosage : dose not exceeding famotidine 40 mg twice daily or equivalent.
–
–
–
| Reference number |
|---|
| # patients |
| HIV/HCV |
| Dose |
| Frequency |
| Cmax |
| AUC |
| 3073 | 3073 |
|---|---|
| 12 | 12 |
| - | - |
| 90/400 mg | 90/400 mg |
| QD | QD |
| - 20%/+ 15% † | - 17%/± 0% †† |
| - 11%/+ 11 † | - 2%/- 5% †† |
| 3073 | 3073 |
|---|---|
| 12 | 12 |
| - | - |
| 40 mg | 40 mg |
| x 1 * | x 1 ** |
Ref #3073 :
* At the same time than ledepasvir/sofosbuvir;
† GS-331007, sofosbuvir active metabolite : AUC +6% and Cmax +6%;
** 12 hours after ledipasvir/sofobuvir;
†† GS-331007, sofosbuvir active metabolite : AUC +6% and Cmax +13%.